Genetix Biotherapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Genetix Biotherapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Genetix Biotherapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Genetix Biotherapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Genetix Biotherapeutics Inc (Genetix Biotherapeutics), formerly bluebird bio Inc, is a commercial-stage biotherapeutics company that is developing genetic therapies for patients with severe rare diseases. The company's gene therapy product includes lovotibeglogene autotemcel for the treatment of sickle cell disease; elivaldogene autotemcel for cerebral adrenoleukodystrophy; and betibeglogene autotemcel for the treatment of transfusion-dependent B-thalassemia. Genetix Biotherapeutics markets its product under the brands LYFGENIA, SKYSONA and ZYNTEGLO. It collaborated with pharmaceutical companies to discover, develop and commercialize gene therapy products. Genetix Biotherapeutics fis headquartered in Somerville, Massachusetts, the US.
Headquarters
United States of America
Address
455 Grand Union Boulevard, Somerville, Massachusetts, 02145
Website
www.genetixbiotx.com
Telephone
1 339 4999300
No of Employees
248
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$83.8M
Genetix Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Lovotibeglogene Autotemcel: Sickle Cell Disease (SCD) | LYFGENIA |
| Elivaldogene Autotemcel: Cerebral Adrenoleukodystrophy (CALD | ZYNTEGLO |
| Betibeglogene Autotemcel: Transfusion-Dependent Β-Thalassemia (TDT) | SKYSONA |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Corporate Changes/Expansions | In September, the company rebranded as Genetix Biotherapeutics Inc. |
| 2025 | Ownership Changes | In June, the company was acquired by Carlyle Group and SK Capital Partners, LP. |
| 2025 | Others | In May, the company amended its definitive agreement to be acquired by Carlyle and SK Capital Partners, LP. |
Competitor Comparison
| Key Parameters | Genetix Biotherapeutics Inc | Vertex Pharmaceuticals Inc | Beam Therapeutics Inc | Agios Pharmaceuticals Inc | Emmaus Life Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Somerville | Boston | Cambridge | Cambridge | Torrance |
| State/Province | Massachusetts | Massachusetts | Massachusetts | Massachusetts | California |
| No. of Employees | 248 | 6,400 | 511 | 539 | 32 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Meek | Chief Executive Officer | Senior Management | - | - |
| Wendy DiCicco | Chief Financial Officer | Senior Management | - | - |
| Tom Klima | Chief Commercial Officer; Chief Operating Officer | Senior Management | 2022 | 53 |
| Ellen Forest | Chief People Officer | Senior Management | - | - |
| Joanne Lager, M.D. | Chief Medical Officer | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer